scholarly journals Three-month pulmonary function and radiological outcomes in COVID-19 survivors: a longitudinal patient cohort study

2020 ◽  
Author(s):  
Xuejiao Liao ◽  
Ying Wang ◽  
Ziyi He ◽  
Yongxing Yun ◽  
Ming Hu ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Hospital Discharge ◽  
Pulmonary Function Tests ◽  
Ground Glass Opacity ◽  
Ground Glass ◽  
High Resolution Computed Tomography ◽  
Airway Function ◽  
Function Test ◽  
Abnormal Pulmonary Function

Abstract Background This study aimed to investigate pulmonary function and radiological outcomes in a group of coronavirus disease 2019 (COVID-19) survivors. Methods 172 COVID-19 survivors in a follow-up clinic in a referral hospital underwent high resolution computed tomography (CT) of the thorax and pulmonary function tests at three month after hospital discharge. Results The median duration from hospital discharge to radiological and pulmonary function test was 90 (interquartile range=88-95) days. The abnormal pulmonary function was found in 11 (6.40%) patients, and abnormal small airway function (FEF25-75%) in 12 (6.98%). Six (3.49%) patients had obstructive ventilation impairment and six (3.49%) had restrictive ventilatory impairment. No significant differences in lung function parameters were observed between the non-severe and severe groups. Of 142 COVID-19 patients performed CT scan, 122 (85.91%) showed residual CT abnormalities and 52 (36.62%) showed chronic and fibrotic changes. The ground-glass opacities absorption in the lungs of severe cases was less satisfactory than that of non-severe patients. The severe paients had higher CT scores than non-severe cases (2.00 versus 0.00, P < 0.001) Conclusion Of the COVID-19 survivors, 6.40% still present pulmonary function abnormality three month after discharge, which did not vary by disease severity during hospitalization. 85.91% patients had abnormalities on chest CT, with fibrous stripes and ground glass opacity as the most common pattern.

scholarly journals Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Matsuo So ◽  
Hiroki Kabata ◽  
Koichi Fukunaga ◽  
Hisato Takagi ◽  
Toshiki Kuno
Keyword(s):  
Systematic Review ◽  
Pulmonary Function ◽  
Hospital Discharge ◽  
Pulmonary Function Test ◽  
Wide Spectrum ◽  
Meta Analysis ◽  
Ground Glass Opacity ◽  
Chest Ct ◽  
Function Test

Abstract Background The coronavirus disease 2019 (COVID-19) causes a wide spectrum of lung manifestations ranging from mild asymptomatic disease to severe respiratory failure. We aimed to clarify the characteristics of radiological and functional lung sequelae of COVID-19 patients described in follow-up period. Method PubMed and EMBASE were searched on January 20th, 2021 to investigate characteristics of lung sequelae in COVID-19 patients. Chest computed tomography (CT) and pulmonary function test (PFT) data were collected and analyzed using one-group meta-analysis. Results Our search identified 15 eligible studies with follow-up period in a range of 1–6 months. A total of 3066 discharged patients were included in these studies. Among them, 1232 and 1359 patients were evaluated by chest CT and PFT, respectively. The approximate follow-up timing on average was 90 days after either symptom onset or hospital discharge. The frequency of residual CT abnormalities after hospital discharge was 55.7% (95% confidential interval (CI) 41.2–70.1, I2 = 96.2%). The most frequent chest CT abnormality was ground glass opacity in 44.1% (95% CI 30.5–57.8, I2 = 96.2%), followed by parenchymal band or fibrous stripe in 33.9% (95% CI 18.4–49.4, I2 = 95.0%). The frequency of abnormal pulmonary function test was 44.3% (95% CI 32.2–56.4, I2 = 82.1%), and impaired diffusion capacity was the most frequently observed finding in 34.8% (95% CI 25.8–43.8, I2 = 91.5%). Restrictive and obstructive patterns were observed in 16.4% (95% CI 8.9–23.9, I2 = 89.8%) and 7.7% (95% CI 4.2–11.2, I2 = 62.0%), respectively. Conclusions This systematic review suggested that about half of the patients with COVID-19 still had residual abnormalities on chest CT and PFT at about 3 months. Further studies with longer follow-up term are warranted.

scholarly journals Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis

2020 ◽  
Vol 14 (11) ◽  
pp. 997-1007
Author(s):  
Sofia A Moll ◽  
Ivo A Wiertz ◽  
Adriane DM Vorselaars ◽  
Pieter Zanen ◽  
Henk JT Ruven ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Vital Capacity ◽  
Mixed Model ◽  
Pulmonary Function Tests ◽  
Hazard Ratio ◽  
Poor Survival ◽  
Function Test

Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxide (estimates respectively: -5.21 and -4.69; p < 0.001). Baseline and 6-month CA 15-3 above 58.5 (hazard ratio: 1.67; p = 0.031) and 50.5 kU/l (hazard ratio: 2.99; p < 0.001), respectively, showed impaired survival compared with lower levels. Conclusion: CA 15-3 is associated with pulmonary function test during follow-up in IPF on antifibrotic treatment. Higher (follow-up) values are related with poor survival. Therefore, CA 15-3 is a promising follow-up biomarker in IPF.

scholarly journals Correlation of Height Parameter and Pulmonary Function Test with Grade of Allergic Rhinitis and Asthma in Children

2020 ◽  
Vol 5 (08) ◽  
pp. 349-352
Author(s):  
Sadaf Choudhary ◽  
Keya Rani Lahiri ◽  
Fehmida Najmuddin
Keyword(s):  
Allergic Rhinitis ◽  
Pulmonary Function ◽  
Pulmonary Function Test ◽  
Pulmonary Function Tests ◽  
Persistent Asthma ◽  
P Value ◽  
Function Tests ◽  
Function Test

Introduction: Allergic Rhinitis and Asthma adversely affects height in children and it could be considered as an objective tool to assess severity, compliance and lung functions in children. We studied the correlation between height and pulmonary function tests with classification of allergic rhinitis and asthma. Aims & Objectives: 1) To study the height parameter with the grade of asthma and allergic rhinitis 2) To evaluate the pulmonary function test with the severity of asthma and allergic rhinitis 3) To correlate height and pulmonary function test with the classification of asthma and allergic rhinitis. Material and Methods: A prospective study including 30 patients in the age group of 5-12 years diagnosed with allergic rhinitis (AR) and bronchial asthma was conducted in a private tertiary care hospital in Navi Mumbai. History was entered in a pre-designed proforma and height was measured using a calibrated stadiometer along with pulmonary function tests recorded at the initial and two visits, 3 months apart. Results: Height increased significantly in patients without AR (p-value<0.01), with mild intermittent (p-value=0.02) and mild persistent AR (p-value<0.01) on subsequent visits. Patients with intermittent, mild persistent and moderate persistent asthma showed a statistically significant increase in height (p-value<0.01) with subsequent assessments. No significant increase in height was noted in patients with moderate persistent AR (p-value=0.14) and severe persistent asthma (p-value=0.16). At baseline, the height correlated significantly with FEV1 (p value<0.01), FVC (p value<0.01), Pre and Post-PEFR (p value<0.01, each). This trend continued at the first follow up. At the second follow-up, height correlated significantly with all parameters of pulmonary function tests (p value<0.01 for FEV1, FVC, FEV1/FVC ratio and PEFR). Conclusion: Height correlation with classification of AR and Asthma along with pulmonary function test has emerged as a simple, safe, cost-effective method in assessing control and monitoring the disease.

scholarly journals Follow-up pulmonary function of COVID-19 patients 4 months after hospital discharge

2021 ◽  
Vol 31 (5) ◽  
pp. 580-586
Author(s):  
Olga I. Savushkina ◽  
Alexander V. Cherniak ◽  
Evgeniy V. Kryukov ◽  
Nataliya A. Aseeva ◽  
Andrey A. Zaytsev
Keyword(s):  
Lung Function ◽  
Pulmonary Function ◽  
Hospital Discharge ◽  
Vital Capacity ◽  
Pulmonary Function Tests ◽  
Complete Recovery ◽  
Lung Diffusion ◽  
Diffusion Capacity ◽  
Lung Capacity

The end of the acute period of COVID-19 does not mean complete recovery. Observation of patients in the post-COVID-19 period showed that a significant number of people experience shortness of breath, fatigue, muscle weakness, sleep disorders, cough, palpitations, so the term post-COVID-19 syndrome was coined. The examination to identify the causes of complaints of COVID-19 convalescents should include lung function assessment.The aim of the study was to assess the dynamics of lung function 4 months after hospitalization for COVID-19.Methods. 31 patients (26 males, the median age was 49 years) underwent traditional pulmonary function tests (PFTs) (spirometry, body plethysmography, test of diffusing lung capacity) and impulse oscillometry (IOS). Results. During the 1st visit, the average PFTs and IOS parameters were within the normal range in the whole group, apart from the diffusing lung capacity (DLCO), which was reduced mildly (on the border with moderate) in 77% of patients. During the 2nd visit, which was conducted on average 102 days after the 1st one, 58% of patients demonstrated abnormal lung diffusion capacity. The second assessment revealed a statistically significant increase in the slow and forced vital capacity (VC and FVC), the forced exhalation volume in 1 second (FEV1), total lung capacity (TLC), DLCO, and a decrease in the ratio of FEV1/FVC and the residual lung volume to TLC ratio.Conclusion. Post-COVID-19 patients show a statistically significant improvement of their lung function 4 months after hospital discharge. A systematic follow-up is essential for such patients to detect lung function abnormalities and correct them.

Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis

2021 ◽  
pp. jrheum.210533
Author(s):  
Kimberly Showalter ◽  
Aileen Hoffmann ◽  
Carrie Richardson ◽  
David Aaby ◽  
Jungwha Lee ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Esophageal Dilation ◽  
Clinical Factors ◽  
High Resolution Computed Tomography ◽  
Mixed Effect ◽  
Mixed Effect Models ◽  
Clinically Significant

Objective To identify clinical factors, including esophageal dilation on chest high-resolution computed tomography (HRCT), that are associated with pulmonary function decline in patients with systemic sclerosis (SSc). Methods Patients fulfilled 2013 SSc criteria and had ≥1 HRCT and ≥2 pulmonary function tests (PFTs). According to published methods, widest esophageal diameter (WED) and radiographic interstitial lung disease (ILD) were assessed, and WED was dichotomized as dilated (≥19mm) vs. not dilated (<19mm). Clinically meaningful PFT decline was defined as %-predicted change in forced vital capacity (FVC) ≥5 and/or diffusion capacity for carbon monoxide (DLCO) ≥15. Linear mixed effect models were used to model PFT change over time. Results 138 SSc patients met study criteria: 100 (72%) had radiographic ILD; 49 (35%) demonstrated FVC decline (median follow-up 2.9y). Patients with Scl-70 autoantibodies had 5- year %-predicted FVC decline (-6.3; 95% CI -9.9, -2.8), while patients without Scl-70 autoantibodies demonstrated 5-year FVC stability (+1.78; 95% CI -0.6, 4.15). Esophageal diameter did not distinguish between those with vs. without FVC decline. Patients with esophageal dilation had statistically significant 5-year %-predicted DLCO decline (-5.6; 95% CI - 10.0, -1.2), but this decline was unlikely clinically significant. Similar results were observed in sub-analysis of patients with radiographic ILD. Conclusion In patients with SSc, Scl-70 positivity is a risk factor for %-predicted FVC decline at five years. Esophageal dilation on HRCT was associated with a minimal, non-clinically significant decline in DLCO and no change in FVC during 5-year follow-up. These results have prognostic implications for SSc-ILD patients with esophageal dilation.

scholarly journals Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Julien Guiot ◽  
Makon-Sébastien Njock ◽  
Béatrice André ◽  
Fanny Gester ◽  
Monique Henket ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Prognostic Factor ◽  
Pulmonary Function ◽  
Lung Disease ◽  
Pulmonary Function Tests ◽  
Serum Levels ◽  
Roc Curve Analysis ◽  
Significant Deterioration ◽  
Lung Dysfunction

AbstractSystemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (ILD), driving its mortality. Specific biomarkers associated with the progression of this lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease. For this, we compared prospectively serum levels of several biomarkers associated with lung fibrosis in SSc patients (n = 102), among which SSc-no ILD (n = 63) and SSc-ILD (n = 39), compared to healthy subjects (HS) (n = 39). We also performed a longitudinal study in a subgroup of 28 patients analyzing biomarkers variations and pulmonary function tests over a period of 2 years. Serum level of IGFBP-2 was significantly increased in SSc patients compared to HS, and negatively correlated with pulmonary function (assessed by carbon monoxide transfer coefficient (KCO)) (r = − 0.29, p < 0.01). Two-year longitudinal analysis in a subgroup of 28 SSc patients determined that IGFBP-2 variation was positively correlated with KCO at 2-year follow-up (r = 0.6, p < 0.001). SSc patients with a lower variation of IGFBP-2 (less than 22%) presented significant deterioration of pulmonary function at 2-year follow-up (p < 0.01). ROC curve analysis enabled us to identify that baseline IGFBP-2 > 105 ng/ml was associated with a poor outcome (KCO < 70% predicted) at 2-year follow-up (AUC = 0.75, p < 0.05). We showed for the first time that serum levels of IGFBP-2 might be a prognostic factor of the development of SSc-ILD.

Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: Long-term follow-up of radiological findings

Lung Cancer ◽  
2008 ◽  
Vol 60 (2) ◽  
pp. 298-301 ◽  
Author(s):  
Hiroshi Soda ◽  
Yoichi Nakamura ◽  
Katsumi Nakatomi ◽  
Nanae Tomonaga ◽  
Hiroyuki Yamaguchi ◽  
...  
Keyword(s):  
Ground Glass Opacity ◽  
Ground Glass ◽  
Radiological Findings ◽  
Invasive Adenocarcinoma ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document